Helsinn Healthcare S.A. v. Sagent Pharmaceuticals, Inc.

I'll research this case thoroughly before drafting. Let me run several searches.

Let me dig deeper into the notable legal issue (the on-sale bar / Helsinn v. Teva Supreme Court case), the IPRs, and the settlement enforcement outcome.

Case Overview: Helsinn Healthcare S.A. v. Sagent Pharmaceuticals, Inc., No. 3:16-cv-00173 (D.N.J.)

Parties and posture. Helsinn Healthcare S.A. is a Swiss research-based pharmaceutical company (headquartered in the Lugano area) that in this case asserted its patents on the branded antiemetic Aloxi® (palonosetron hydrochloride injection) — NDA No. 021372, which Helsinn holds and markets in the U.S. Helsinn is an operating innovator company, not an NPE/PAE; co-plaintiff/co-owner Roche Palo Alto LLC also appears on the docket for some of the patents (Patexia; NDA records). Sagent Pharmaceuticals, Inc. is a U.S. specialty generics maker of injectable products (corporate office in Schaumburg, Illinois, per the declaration of EVP Donald R. Bullock, D.I. 48-1). Helsinn filed this Hatch-Waxman action on January 11, 2016, after Sagent's ANDA No. 205870 included Paragraph IV certifications against each asserted patent; a companion suit, No. 3:16-cv-00681, followed on February 8, 2016, as to Sagent's second ANDA No. 204289. Both ANDAs cover the same approved strength — palonosetron HCl 0.25 mg base/5 mL (0.05 mg base/mL) — and both received tentative FDA approval blocked by the first-filers' 180-day exclusivity (Sagent D.I. 48/53, 71). The cases were dismissed August 2, 2016 by consent judgment pursuant to a settlement, with the court retaining jurisdiction to enforce it. Sagent reopened the case in May 2018 (D.I. 48/51) moving to enforce that settlement amid a launch-timing dispute over the 180-day exclusivity window (Teva launched "at-risk" March 23, 2018; Dr. Reddy's March 26; Sandoz April 2; Sagent's own final approval came September 19, 2018). The docket shows extensive briefing, discovery of the Dr. Reddy's/Sandoz settlements, and an order on the motion (D.I. 66); DrugPatentWatch lists the case as terminated July 18, 2018. Note: I could not verify the precise disposition/text of the settlement-enforcement ruling from the sources reviewed, so the exact outcome should be confirmed against the order.

Accused technology and patents. The accused products are Sagent's generic palonosetron HCl single-use-vial injections, bioequivalent to Aloxi (an intravenous 5-HT₃ antagonist used to prevent chemotherapy-induced nausea and vomiting and postoperative nausea/vomiting). The five asserted patents are all in the same family — "Liquid pharmaceutical formulations of palonosetron," priority January 30, 2003, issued 2011–2014 — and each asserted claim covers the 0.25 mg/5 mL dose (Fed. Cir. 2017 summary, 855 F.3d 1356): U.S. 7,947,724 and 7,947,725 ('724,'725) and 7,960,424 ('424) claim a 0.05 mg/mL palonosetron formulation with EDTA (0.005–1.0 mg/mL) and mannitol (10–80 mg/mL), stable at room temperature for 24 months (asserted claims 2 & 9, claim 2, and claim 6, respectively); U.S. 8,598,219 ('219) claims a fixed dose of 0.25 mg palonosetron in a 5 mL solution with EDTA (asserted claims 1, 2, 6); and U.S. 8,729,094 ('094), a later continuation, covers the same 0.25 mg/5 mL subject matter. All were Orange Book–listed with July 30, 2024 expiration including pediatric exclusivity. In the parallel Teva/Dr. Reddy's litigation, the district court upheld the '724, '725 and '424 patents as valid and infringed, but the '219 patent was held invalid under the AIA on-sale bar — a ruling that became final.

Why the case is notable. This docket is a footnote in one of the most consequential patent-law rulings in recent memory: the asserted '219 patent was the patent at issue in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019), in which a unanimous Supreme Court held that an inventor's "secret sale" to a confidentiality-bound third party can place an invention "on sale" under AIA § 102(a)(1). That ruling traced directly to Helsinn's 2001 license/supply agreements with MGI Pharma and to Helsinn's parallel D.N.J. Hatch-Waxman suits over Aloxi (the Federal Circuit decision at 855 F.3d 1356 (2017) reversed the district court's on-sale-bar holding). The Sagent case thus sits inside a sprawling Aloxi generic campaign: Helsinn sued at least fifteen ANDA sponsors, and challengers repeatedly tried — and failed — to get PTAB institution on these patents (e.g., Accord's '219 IPR and Dr. Reddy's IPRs on the '094 and '942 patents were denied institution in 2014–2016, per patent-analytics aggregators). The commercial stakes were the fast-following generic palonosetron market: the first filers (Teva, Dr. Reddy's, Sandoz) shared 180-day exclusivity and launched in spring 2018, several at risk, while Sagent and other settlors had to litigate launch timing — the very dispute that revived this case in 2018. Venue in the District of New Jersey mattered because the district (notably in the consolidated Helsinn v. Dr. Reddy's/Teva action before Judge Cooper) had become the central forum for Aloxi ANDA litigation, and the Federal Circuit's Acorda personal-jurisdiction line made D.N.J. a magnet for these cases against out-of-state generics (see, e.g., Helsinn v. Hospira). The case was assigned to Judge Stanley R. Chesler, with Magistrate Judge Cathy L. Waldor (2:16-cv-00173-SRC-CLW); Helsinn was represented by Saul Ewing LLP (Charles M. Lizza) and Paul Hastings LLP, and Sagent by Taft Stettinius & Hollister LLP (Stephen R. Auten) and Carella Byrne (Melissa E. Flax).

Sourcing/uncertainty note: Party roles, ANDA numbers, patent sketches, docket events, and the settlement-enforcement dispute are well documented in the parties' briefs on CourtListener (D.I. 48, 53, 71) and FDA approval letters; the Supreme Court and Federal Circuit holdings on the '219 patent are authoritative. The exact procedural outcome of Sagent's 2018 motion to enforce, and Sagent's corporate ownership history (reported acquisition by Nichi-Iko in 2016 — not verified in the sources I reviewed), should be confirmed against PACER/primary documents.

I'll research this case across multiple sources. Let me start with several parallel searches.

I have strong background on the litigation family. Now let me drill into the Sagent-specific docket, settlement enforcement, and PTAB proceedings.

Helsinn Healthcare S.A. v. Sagent Pharmaceuticals, Inc., No. 3:16-cv-00173 (D.N.J.) — Legal Developments & Outcome

A caveat up front: Sagent's case is the least-reported member of the Helsinn/Aloxi® ANDA family. It never reached Markman or trial; it was resolved by settlement and then re-opened for a motion to enforce that settlement. Most of what is publicly documented comes from the briefing on that motion (D.I. 51/53/57/71 in the Sagent docket) rather than from opinions. I flag below where I am inferring rather than sourcing.

Note on the number: PACER/CourtListener docket the case as 2:16-cv-00173-SRC-CLW (D.N.J., Newark vicinage) after reassignment from Hon. Mary L. Cooper (Trenton, where it was filed as 3:16-cv-00173); the current judge is Hon. Stanley R. Chesler, with Magistrate Judge Cathy L. Waldor. The 2-/3- prefix change reflects the vicinage reassignment.

---

1. Filing and initial pleadings (January–February 2016)

Answer/counterclaims: The public record I could retrieve does not include Sagent's answer and counterclaims in 16-173 as a standalone document. The standard Hatch-Waxman response would be an answer asserting invalidity (including § 102 on-sale, § 103 obviousness, § 112) and non-infringement. **I cannot cite a specific docket entry for it, so I am not asserting it

I'll research the counsel of record for Helsinn Healthcare S.A. in this matter.

Let me dig into the plaintiff's specific appearances and the Paul Hastings team.

Let me pull the specific docket entries and the complaint's caption block for this case.

Counsel of Record for Plaintiff Helsinn Healthcare S.A.

Helsinn Healthcare S.A. v. Sagent Pharmaceuticals, Inc., No. 3:16-cv-00173 (SRC)(CLW) (D.N.J.)

Structure of the representation. This was a two-firm (plus a third for the co-plaintiff) arrangement typical of Helsinn's ALOXI® (palonosetron HCl) Hatch-Waxman program:

• New Jersey local counsel: Saul Ewing LLP (Newark) — filed the complaint and all substantive NJ filings.
• Lead trial/outside counsel: Paul Hastings LLP (New York) — listed as "Of Counsel" on the complaints and handled the substantive patent work.
• Counsel for co-plaintiff Roche Palo Alto LLC: Loeb & Loeb LLP (New York).

This structure is confirmed on the docket itself: Saul Ewing's D.I. 58 letter (June 8, 2018) states, "This firm, together with Paul Hastings LLP, represents plaintiff Helsinn Healthcare S.A. ("Helsinn") in the above-captioned action." (D.I. 58; CourtListener docket 6127735)

---

1. Saul Ewing LLP — Newark, NJ (local counsel / NJ counsel of record)

One Riverfront Plaza, Suite 1520, Newark, NJ 07102-5426 | (973) 286-6700

---

2. Paul Hastings LLP — New York, NY (lead / "Of Counsel" — substantive patent counsel)

75 East 55th Street, New York, NY 10022 | (212) 318-6000

---

3. Loeb & Loeb LLP — New York, NY (co-plaintiff's counsel)

345 Park Avenue, New York, NY 10154 | (212) 407-4000

---

Sourcing/caveats

• Directly confirmed for this docket: Saul Ewing (Lizza, Baton, Sullivan) and Paul Hastings (Dittmann, Ni) via Notices of Appearance and D.I. 58 in 2:16-cv-00173, plus Patexia's Case 3:16-cv-00173 attorney record for Charles M. Lizza.
• Strongly supported but reconstructed from parallel filings: The full Paul Hastings "Of Counsel" roster (O'Malley, Wexler, Ashkenazi, Ji, and in related complaints Weir/Park). I could not retrieve the caption/counsel block of D.I. 1 in 16-cv-173 itself within the search budget, so the exact Paul Hastings signature block on this complaint may differ by one or two names. Treat Weir and Park as "named in the closely related Helsinn ALOXI® complaints of the same period," not as verified appearances in 16-cv-173.
• Pro hac vice: The docket shows pro hac vice admissions for Sagent's out-of-state counsel (Stephen R. Auten and Brian P. Murray of Taft Stettinius). I did not find a corresponding PHV order for the Paul Hastings attorneys for Helsinn in this docket; Dittmann and Ni nonetheless appear on the docket via Notices of Appearance, and all Paul Hastings attorneys are listed as "Of Counsel" (i.e., not the NJ counsel of record).
• No sealed-counsel issue: The representation here is public. Nothing in the docket suggests Helsinn used undisclosed or in-house counsel; I found no in-house Helsinn attorney of record. If Helsinn's in-house legal team (e.g., its General Counsel's office in Lugano/Switzerland or its U.S. subsidiary) was involved, it did not appear on this docket.
• Case status: Claims between Helsinn and Sagent were dismissed pursuant to settlement (consent judgment/dismissal orders), but the court retained jurisdiction to enforce the Sagent Settlement — which is why Sagent moved to reopen and to enforce in May 2018 (D.I. 46–47, 51, 53), with Saul Ewing and Paul Hastings responding for Helsinn.

I'll research the defendant's counsel of record, verifying against docket sources and firm records.

Let me verify additional counsel appearances and the pro hac vice history.

Counsel of Record for Defendant Sagent Pharmaceuticals, Inc.

Bottom line: Sagent was represented by a two-firm team throughout the life of this case and in the companion action (No. 3:16-cv-00681): Taft Stettinius & Hollister LLP (Chicago) as lead/outside Hatch-Waxman counsel, and Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C. (Roseland, N.J.) as New Jersey local counsel. The same team carried the defense of Sagent's 2018 motion practice to enforce the settlement agreement.

Appearing counsel

In-house / other

No Sagent in-house attorney entered a notice of appearance on this docket that I could locate. Sagent's factual record was supplied by Donald R. Bullock, an EVP who executed the harm declaration (D.I. 48-1), but he is a client declarant, not counsel.

Sourcing and caveats

• Attorney signatures, firms, addresses and e-mail addresses are taken directly from the Sagent filings' caption blocks: D.I. 46-1 (May 11, 2018), D.I. 70 (June 26, 2018), and D.I. 71 (June 27, 2018), all available on CourtListener (docket 6127735), which print Flax/Cross (Carella Byrne) and Auten/Murray (Taft, Chicago) as "Attorneys for Defendant Sagent Pharmaceuticals, Inc."
• The pro hac vice admissions and the Daignault withdrawal appear on the Plainsite docket summary for the case ("CONSENT ORDER Granting admission of Stephen R. Auten, Esq. and Brian P. Murray, Esq. to appear Pro Hac Vice"; "ORDER Granting withdrawal of Pro Hac Vice Motions… on behalf of Ronald M. Daignault… Signed by Magistrate Judge Douglas E. Arpert on 4/5/2016"), which I could not independently verify against PACER.
• Consistency check with the prior summary: the earlier section named "Taft Stettinius & Hollister LLP (Stephen R. Auten) and Carella Byrne (Melissa E. Flax)" — that is correct but incomplete; it omits Michael Cross, Brian P. Murray, Roshan Shrestha, and the withdrawn Daignault motion, all of which I've added here.
• Because the case is long settled (dismissed by consent Aug. 2, 2016; enforcement proceedings closed in 2018), no counsel has appeared since; the firm/role notes above describe the 2016–2018 record, not current representations.